Among the radiopharmaceuticals designed for ER imaging, the Food and Drug Administration recently approved the use of 16α-[18F]17β-estradiol (18F-FES) for PET imaging (FES-PET) in metastatic ER+ BC patients, while the approval by the European Medicine Agency is under evaluation. This evidence concerns the gene ESR1 and breast cancer.